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Abstract Purpose: To evaluate
whether cystatin C in serum (sCyC)
and urine (uCyC) can predict early
acute kidney injury (AKI) in a mixed
heterogeneous intensive care unit
(ICU), and also whether these bio-
markers can predict the need for renal
replacement therapy (RRT). Meth-
ods: Multicenter prospective
observational cohort study in patients
C18 years old and with expected ICU
stay C72 h. The RIFLE class for AKI
was calculated daily, while sCyC and
uCyC were determined on days 0, 1,
and alternate days until ICU dis-
charge. Test characteristics were
calculated to assess the diagnostic
performance of CyC. Results: One
hundred ﬁfty-one patients were stud-
ied, and three groups were deﬁned:
group 0 (N = 60), non-AKI; group 1
(N = 35), AKI after admission; and
group 2 (N = 56), AKI at admission.
We compared the two days prior to
developing AKI from group 1 with
the ﬁrst two study days from group 0.
On Day –2, median sCyC was sig-
niﬁcantly higher (0.93 versus
0.80 mg/L, P = 0.01), but not on
Day –1 (0.98 versus 0.86 mg/L,
P = 0.08). The diagnostic perfor-
mance for sCyC was fair on Day –2
[area under the curve (AUC) 0.72]
and poor on Day –1 (AUC 0.62).
Urinary CyC had no diagnostic value
on either of the two days prior to AKI
(AUC\0.50). RRT was started in 14
patients with AKI; sCyC and uCyC
determined on Day 0 were poor pre-
dictors for the need for RRT (AUC
B0.66). Conclusions: In this study,
sCyC and uCyC were poor biomark-
ers for prediction of AKI and the need
for RRT.
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Acute kidney injury (AKI) is a common complication of
critical illness and carries high mortality despite signiﬁ-
cant advances in medical care [1, 2]. This apparent lack of
improvement may result from the use of more aggressive
medical and surgical interventions in an ever-ageing
population [3]. On the other hand, potentially effective
therapeutic interventions for AKI may currently fail
because they are applied late in the course of injury after
an obvious increase of serum creatinine (sCr) is observed
[4]. Due to the delayed rise in sCr following injury, recent
efforts have focused on identiﬁcation of an early and
reliable biomarker of kidney injury [5, 6].
Cystatin C (CyC) is a 13-kDa, nonglycosylated basic
protein,producedataconstantratebyallnucleatedcells.Itis
freely ﬁltered by glomeruli and catabolized in tubules. In
high-risk patients, serum CyC (sCyC) detected AKI
1–2 days earlier than sCr [7]. Moreover, although CyC is
normally not detected in urine, it has been found in urine of
patients with tubular disease, suggesting that it is a tubular
marker [8–13]. One drawback of use of CyC at present is a
lackofrecognitionofitspotentialvalueforuseinthegeneral
criticalcaresetting,inwhichthepopulationisheterogeneous
and AKI etiology and timing are often unclear.
In the present study in a heterogeneous intensive care
unit (ICU) population we collected serial samples of
sCyC and uCyC, and determined the ﬁrst day of AKI
based on the RIFLE classiﬁcation system [14]. We
hypothesized that these markers predict AKI 1–2 days
earlier than the RIFLE criteria in patients developing AKI
after entry, and that these biomarkers predict the need for
renal replacement therapy (RRT) on the ﬁrst day of AKI.
The preliminary ﬁndings of this study were presented in
abstract form [15].
Concise methods
Patients
The protocol was approved by the institutional review board
of all participating institutions, and written informed consent
was obtained from all patients or their authorized represen-
tatives. The study was a prospective observational cohort
study in adult patients with expected duration of mechanical
ventilationofatleast48 h,and/orexpectedlengthofICUstay
of at least 72 h. Patients were enrolled within 48 h of ICU
admission. Detailed methods (e.g., exclusion criteria) are
describedinElectronicSupplementaryMaterial(ESM)ﬁle1.
Demographic data, admission diagnosis, Acute Phys-
iology and Chronic Health Evaluation (APACHE) II, and
Simpliﬁed Acute Physiology Score (SAPS) II scores were
documented upon ICU admittance [16, 17]. Routine lab-
oratory data were measured daily.
Deﬁnition of acute kidney injury
The patients were scored daily for AKI using the creati-
nine and urine output criteria of the RIFLE classiﬁcation
system for AKI [14]. To deﬁne the baseline renal function
we compared the premorbid sCr within 1 year prior to
ICU admission with the sCr at ICU admission. The lower
of these two values served as baseline renal function. If
the premorbid sCr was unavailable, it was estimated by
solving the modiﬁcation of diet in renal disease (MDRD)
equation as recommended by the Acute Dialysis Quality
Initiative (ADQI) working group [18].
The premorbid sCr was not estimated in patients with
history of kidney insufﬁciency. In these patients, admis-
sion sCr served as baseline when the premorbid sCr was
unknown.
The ﬁrst day of AKI was termed Day 0, while the two
days prior to this day were termed Day -1 and Day -2,
respectively.
Sampling and measurement of cystatin C
Blood and urine sampling for CyC measurements were
performed on inclusion, day 1 and alternate days until the
start of RRT, or ICU discharge. Samples were centrifuged
at 1,500 9 g for 10 min at 4C. The supernatants were
stored at –80C until assayed batchwise. Cystatin C was
measured with an N Latex Cystatin C test kit, a particle-
enhanced immunonephelometric method, on a BN ProS-
pec analyzer (Dade Behring, Leusden, The Netherlands).
Urea and creatinine levels were measured by standard
clinical chemical methods. We normalized urinary
excretion of CyC for millimoles of urinary creatinine
(uCyCcorr) to compensate for differences in urine ﬂow
rate [19].
Statistical analysis
The primary endpoint was the ﬁrst RIFLE event (risk,
injury or failure). The secondary endpoint was initiation
of RRT. Data were analyzed using the Statistical Package
for the Social Sciences (SPSS) version 17.0 (SPSS, Chi-
cago IL, USA) for Windows. Continuous variables are
expressed as mean ± standard deviation (SD) or median
with interquartile range. Cystatin C levels below the
detection limit of 0.05 mg/L were considered to be
0.025 mg/L. Categorical variables are expressed as counts
and percentages. Normally distributed variables were
compared using one-way analysis of variance with Bon-
ferroni’s correction for multiple comparisons. For
signiﬁcant ﬁndings, post hoc t-test was applied. Kruskall–
Wallis one-way analysis of variance was used to compare
non-normally distributed variables. Chi-square testing
was used to test frequencies between groups. Linear
494mixed models were used to compare CyC levels among
RIFLE stages. All testing was two-tailed, and P\0.05
was considered statistically signiﬁcant. Test characteris-
tics were calculated to assess the diagnostic performance
of CyC.
Results
Patients
We enrolled 170 patients from April 2006 to November
2007 and excluded 19 patients during the analysis because
of incomplete sampling, leaving 151 patients for analysis.
One hundred thirty-three patients (88%) were included on
the ﬁrst day of ICU admission, and 18 patients (12%)
were included the next day of admission. We deﬁned
three groups: group 0 (N = 60), never developed AKI,
serving as controls; group 1 (N = 35), developed AKI
after admission; and group 2 (N = 56), presented with
AKI at admission. AKI developed after a median of 2
[1–2] days (range 1–7 days) in group 1: 17 patients (49%)
were classiﬁed for AKI by the creatinine criteria, 14
patients (38%) by the urine criteria, and in 3 patients (9%)
the creatinine and urine scores were identical. In group 2,
28 patients (50%) had AKI at admission by the creatinine
criteria, 13 patients (23%) by the urine criteria, and in 17
patients the creatinine and urine scores were identical.
Table 1 compares the baseline clinical data of the three
groups, while renal and outcome data are shown in
Table 2. The maximum RIFLE class was higher in
group 2 compared with group 1. In group 1 the maximum
RIFLE class was achieved by the creatinine criteria in 21
patients (60%), by the urine criteria in 8 patients (23%),
and in 6 patients (17%) the creatinine and urine AKI
classiﬁcation were identical. In group 2 the maximum
RIFLE class was achieved by the creatinine criteria in 24
patients (43%), by the urine criteria in 13 patients (23%),
and in 17 (30%) patients the creatinine and urine AKI
classiﬁcation were identical.
Serum and urinary cystatin C levels
Cystatin C was measured in 582 blood samples
(3.8 ± 3.2 samples/patient) and 569 urine samples
(3.8 ± 3.1 samples/patient). Cystatin C level was below
the detection limit in 171 (30%) urine samples. Serum
CyC levels increased signiﬁcantly with increasing RIFLE
class (Table 3). Urinary CyC levels also increased with
increasing RIFLE class; however, the difference between
RIFLE risk and RIFLE injury was not statistically
signiﬁcant.
Figure 1 compares the longitudinal trend of sCr,
sCyC, and uCyC starting from 2 days prior to AKI
(group 1) with the non-AKI trend (group 0). On Day –2,
median sCyC was signiﬁcantly higher (0.93 versus
0.80 mg/L, P = 0.01), but not on Day –1 (0.98 versus
0.86 mg/L, P = 0.08). Serum CyC levels, however, did
Table 1 Baseline characteristics grouped according to AKI status
Group 0 (N = 60) Group 1 (N = 35) Group 2 (N = 56) P
Age (years) 59.2 ± 16.1 68.4 ± 15.4 74.6 ± 9.3 \0.001
Male (%) 39 (65) 24 (69) 34 (62) 0.81
BMI (kg/m
2) 24.6 ± 4.3 26.5 ± 3.8 29.6 ± 12.8 0.11
APACHE II 18.5 ± 9.9 19.6 ± 8.3 24.2 ± 12.9 0.016
SAPS II 37.2 ± 13.3 44.1 ± 14.2 47.6 ± 16.4 0.01
Comorbidities (%)
Hypertension 15 (26) 14 (40) 24 (44) 0.12
Diabetes 7 (12) 5 (14) 8 (15) 0.92
CKD 2 (3) 1 (3) 6 (11) 0.17
TSH (mU/L) 0.40 (0.18–0.87) 0.42 (0.25–1.0) 0.41 (0.21–1.20) 0.83
FT4 (pmol/L) 13.2 ± 3.5 12.8 ± 3.3) 13.6 ± 3.6 0.67
Admission category (%) 0.68
Medical 29 (48.3) 17 (48.6) 23 (41.8)
Surgical 31 (51.7) 18 (51.4) 33 (59)
Primary diagnosis (%) 0.21
Cardiovascular failure 2 (3.3) 4 (11.4) 4 (7.1)
Cerebrovascular event 2 (3.3) 0 0
Hemorrhagic shock 7 (11.7) 2 (5.7) 6 (10.7)
Multiple trauma 4 (6.7) 2 (5.7) 1 (1.8)
Elective major surgery 1 (1.7) 1 (2.9) 5 (8.9)
Respiratory failure 23 (38.3) 11 (31.4) 14 (25)
Septic shock 20 (33.3) 13 (37.1) 26 (46.6)
AKI acute kidney injury, group 0 no AKI, group 1 developed AKI
after admission, group 2 AKI at admission. BMI body mass index,
APACHE Acute Physiology and Chronic Health Evaluation, SAPS
Simpliﬁed Acute Physiology Score, CKD chronic kidney disease,
TSH thyroid-stimulating hormone
495not rise earlier than sCr. On the 2 days prior to AKI,
uCyC levels did not differ signiﬁcantly between group 1
and group 0 (median 0.13 [0.025–0.88] mg/L versus
median 0.16 [0.025–1.50] mg/L, P = 0.89, and median
0.14 [0.025–0.37] mg/L versus median 0.17 [0.025–0.84]
mg/L, P = 0.57, Day –2 and Day –1, respectively). The
Table 2 Renal characteristics and outcome grouped according to AKI status
Group 0 (N = 60) Group 1 (N = 35) Group 2 (N = 56) P
Premorbid sCr (lmol/L)
Actual
a 92 ± 30 (N = 37) 91 ± 25 (N = 28) 83 ± 23 (N = 37) 0.31
Estimated
b 88 ± 12 86 ± 12 83 ± 11 0.05
Study inclusion
sCr (lmol/L) 72 (61–94) 87 (76–87) 139 (97–211) \0.001
sCyC (mg/L) 0.80 (0.65–1.04) 0.91 (0.81–1.17) 1.14 (0.88–1.94) \0.001
uCyC (mg/L) 0.16 (0.025–1.47) 0.18 (0.07–0.68) 0.59 (0.10–3.47) 0.46
uCyCcorr (g/molCr) 0.03 (0.01–0.30) 0.04 (0.01–0.13) 0.13 (0.01–0.67) 0.47
Maximum RIFLE class (%) \0.001
Risk – 27 (77) 22 (39.3)
Injury – 5 (14.3) 14 (25)
Failure – 3 (8.6) 20 (35.8)
CVVH (%) 1 (1.7) 4 (11.4) 10 (17.6) 0.01
ICU treatment (days) 5 (3–8) 8 (5–18) 6 (3–9) 0.002
ICU mortality (%) 0 4 (11.4) 11 (19.6) 0.002
Hospital mortality (%) 4 (6.7) 6 (17.1) 18 (32.1) 0.002
AKI acute kidney injury, group 0 never AKI, group 1 developed
AKI after admission, group 2 AKI at admission, sCr serum creat-
inine, sCyC serum cystatin C, uCyC urine cystatin C, uCyCcorr
urine cystatin C normalized for urinary creatinine, CVVH contin-
uous venovenous hemoﬁltration, ICU intensive care unit
a Baseline serum creatinine based on premorbid serum creatinine
within 1 year prior to ICU admission
b Baseline serum creatinine based on solving the modiﬁcation of
diet in renal disease (MDRD) equation [18]
Table 3 Cystatin C per RIFLE class
None Risk Injury Failure P
Serum samples
Number 399 109 35 31
CyC (mg/L) 1.15 (1.05–1.25) 1.34 (1.22–1.45) 1.75 (1.59–1.92) 2.31 (2.09–2.52) \0.001
Urine samples
Number 391 104 40 34
CyC (mg/L) 1.02 (0.54–1.51) 2.36 (1.52–3.19) 2.77 (1.43–4.12) 5.87 (4.24–7.51) \0.001
CyCcorr (g/mol Cr) 0.43 (0.28–0.59) 0.44 (0.21–0.68) 0.34 (-0.04–0.72) 0.79 (0.32–1.24) 0.46
Values are mean and 95% conﬁdence interval. The P value represents the difference among groups by linear mixed models
sCyC serum cystatin C, uCyC urine cystatin C, uCyCcorr uCyC normalized for urinary creatinine
Fig. 1 Time course of serum creatinine, serum cystatin C, and urine
cystatin C. Time courses are from 2 days prior to acute kidney injury
(AKI) for patients developing AKI after entry (open circles), and from
entry for the non-AKI group (closed circles). Values are mean and
standard error of the means. The number of patients investigated is
shown in italics at each time point. * P\0.05 compared with the non-
AKI group
496diagnostic performance for sCyC was fair on Day –2
[area under the curve (AUC) 0.72] and poor on Day –1
(AUC 0.62), while uCyC had no diagnostic value on
Day –2 and Day –1 (Fig. 2). The test characteristics of
sCyC at various cutoff levels are shown in ESM Table 1.
Fourteen (15%) out of 91 AKI patients received contin-
uous venovenous hemoﬁltration (CVVH): 4 patients from
group 1, and 10 patients from group 2. Median duration
between Day 0 and initiation of CVVH was 1.5 [0–4] days.
In comparison with the non-CVVH patients, the AKI
patients requiring CVVH had signiﬁcantly higher APA-
CHE II scores on admission (28 [21–33] versus 19 [14–27],
P = 0.01) and produced less urine (740 [400–1,088] mL/
day versus 1,660 [1,028–2,918] mL/day, P = 0.001). Sys-
temic and urinary CyC determined on Day 0 were poor
predictors for the need for RRT (AUC B 0.66, Fig. 3).
Discussion
In this prospective multicenter cohort study in a hetero-
geneous ICU population, sCyC and uCyC increased with
increasing RIFLE class. However, the predictive ability of
these biomarkers for AKI was poor. Approximately one-
third of the patients without AKI at ICU admission devel-
oped AKI during the ICU treatment, and in these patients
sCyC was signiﬁcantly higher 2 days prior to AKI com-
pared with patients who did not develop AKI. Of note,
sCyC levels did not rise earlier than sCr. The diagnostic
performance of sCyC was at best fair for Day –2 and poor
on Day –1. Levels of uCyC were not different in patients
prior to AKI in comparison with patients who did not
develop AKI and had no diagnostic accuracy for AKI.
Previous studies investigating whether CyC increases
before development of AKI are limited and their results
inconsistent; however, comparison among studies is
hampered by case mix and heterogeneity in study designs
[7, 12, 20–24]. Notably, no two studies used identical
deﬁnitions for AKI, and this deﬁnition is critical in bio-
marker research. Nejat et al. [20, 25, 26] recently reported
on the predictive performance of CyC in two subanalyses
of the EARLYARF study. Notably, while 3,966 patients
were screened for the EARLYARF study, only 444
patients (11%) were included in the subanalyses, sug-
gesting selection bias [25]. Based on the sCr criteria used
Fig. 2 Receiver-operating curves demonstrating the performance
of cystatin C (CyC) for prediction of acute kidney injury (AKI).
Upper panels 2 days prior to AKI (N = 71, disease prevalence
0.20); lower panels 1 day prior to AKI. (N = 81, disease preva-
lence 0.35). Area under the curve (AUC) is depicted in each panel.
uCyCcorr urine cystatin C normalized for urinary creatinine
497by the Acute Kidney Injury Network deﬁnition [27], 125
(28%) patients had AKI on entry, 73 (16%) patients
developed AKI over the subsequent 7 days (AKI 7d), and
246 (55%) patients did not [20, 26]. sCyC rose prior to
sCr in 66% of the patients developing AKI after entry
[20]. sCyC on entry was predictive for sustained AKI
(AUC 0.80), deﬁned as an increase in sCr of at least 50%
from baseline for 24 h or longer, but not for AKI 7d
(AUC 0.65) [20]. A subanalysis of sepsis patients showed
that only uCyC was predictive of AKI within 48 h (AUC
0.71) and not sCyS, while uCyC was not predictive of
AKI in patients without sepsis (AUC = 0.45) [26]. Ah-
lstro ¨m et al. [21] studied 202 patients in a mixed ICU, of
whom 49 developed AKI according to the urine output
and/or sCr RIFLE failure criteria. In that study sCyC
showed excellent predictive value for AKI; however,
sCyC did not rise earlier than sCr [21]. Herget-Rosenthal
et al. [7] analyzed 85 ICU patients at high risk of devel-
oping AKI and used the creatinine risk criteria of the
RIFLE classiﬁcation to deﬁne AKI (N = 44). In contrast
to our ﬁndings, sCyC was shown to detect AKI 1–2 days
earlier than sCr (AUC 0.82 and 0.97 on day –2 and
day –1, respectively) [7]. In the study by Haase-Fielitz
et al. [23] in 100 patients following cardiopulmonary
bypass surgery (CPB), 23 patients developed AKI,
deﬁned as increase in sCr of C50% from baseline within
the ﬁrst ﬁve postoperative days. In that study, sCyC on
ICU arrival and at 24 h after CPB were good predictors of
AKI (AUC & 0.83). Notably, the authors suggested that
presence of chronic kidney disease (CKD) could affect
the diagnostic performance of CyC, because exclusion of
the CKD patients reduced the diagnostic performance of
sCyC. This reduction in diagnostic performance, how-
ever, may have been caused by the smaller sample size
(N = 15), rather than by the exclusion of CKD patients
[23]. We did not evaluate the effect of CKD, because only
one patient had CKD on day –2 and day –1. In another,
small (N = 30) CPB study, 15 patients developed AKI
deﬁned as 50% or greater increase in sCr from baseline
within 72 h, and the optimal diagnostic performance for
sCyC(AUC0.83)was10 hpostCPB[22].IntheCPBstudy
(N = 72) of Koyner, 34 patients developed AKI deﬁned as
sCr rise of C25% from baseline within the ﬁrst 3 days or
needofRRT[12].SerumCyCatICUarrivalandat6 hwere
poor predictors for AKI (AUC 0.62 and 0.63, respectively),
whileurineCyCatICUarrivalandat6 hwerefairpredictors
(AUC 0.69 and 0.72, respectively) [12]. In the study by
Liangoset al.[24](N = 103),uCyCmeasured2 hpostCPB
did not predict AKI (N = 13), deﬁned as sCr increase
of C50%frompostCPBtopeakvaluewithintheﬁrst3 days
(AUC0.50).Inaverysmallstudyinsepticpatients(N = 29)
no correlation was found between sCyC at ICU admission
andoccurrenceofAKI(N = 10)deﬁnedassCr[267 lmol/
L or diuresis \30 mL/h [28]. Four small studies in ICU
patients reported that sCyC was superior to sCr to identify
glomerular ﬁltration rate (GFR)\80 mL/min per 1.73 m
2
[29–32]. The GFR studies, however, can be criticized
becausetheyusedderivativesforGFRandnotthereal‘‘gold
standard’’ based on clearance of exogenous substances [33].
In the present study, 56 (37%) patients had AKI at
admission, which is similar to a previous AKI biomarker
study in a heterogeneous ICU population [34]. It make little
sensetopredictAKIinpatientswithAKI;however,inthese
patients, CyC may help to identify those requiring RRT.
Unfortunately,inourstudybothsCyCanduCyCdetermined
onday 0werepoorpredictorsfortheneedforRRT,although
it must be mentioned that RRT was started in 14 patients
only. Our ﬁndings agree with the ﬁndings of Perianayagam
et al. [35], but disagree with three earlier reports suggesting
excellent diagnostic performance of sCyC [11, 20, 23].
Severalfactorsmayexplaintheconﬂictingresults,including
casemixandthereasonforstartingRRT.Inourstudy,oligo/
anuria often triggered RRT, while low GFR probably trig-
geredRRTinthestudybyHerget-Rosenthalet al.,including
exclusivelynonoliguricpatients[11].InthestudybyHaase-
Fielitz et al. only ﬁve patients fulﬁlled the composite end-
point (need for RRT and in-hospital mortality) [23]. Nejat
et al. do not report how many patients received RRT [20].
Fig. 3 Receiver-operating curves demonstrating the performance of cystatin C (CyC) for prediction of the need of renal replacement
therapy. (N = 80, disease prevalence 0.16). Area under the curve (AUC) is depicted in each panel
498Another potential role for biomarkers is to allow differ-
entiation between extrinsic and intrinsic causes of AKI;
however,ourstudywasnotdesignedtoinvestigatethisissue.
Nearly 40% of our patients never developed AKI, yet
someofthesepatientshadincreasedlevelsofCyCaccording
to the reference intervals reported in literature [10]. Several
factors may be responsible for this ﬁnding. First, the pub-
lished reference intervals were determined in healthy
volunteerswithnohistoryofrenaldisease,andmaynotapply
to our critically ill population. Although sCyC is less inﬂu-
enced by age, sex, and muscle mass compared with serum
creatinine level, it still can be affected by these patient vari-
ables[36].Moreover,sCyClevelscanbeaffectedbylevelsof
glucocorticosteroids[37],thyroidhormones[38],andinsulin
[39] as well as markers of inﬂammation such as white blood
cell count and C–reactive protein level [40]. All these factors
playanimportantroleincriticallyillpatientsandcouldaffect
the reference interval. Second, we did not use any protease
inhibitor in the storage of the urine to clear all disturbing
elements in the urine. However, Herget-Rosenthal reported
good agreement between uCyC measurement with and
without stabilization buffer [10]. Finally, the consensus
RIFLEdeﬁnitionforAKIisbasedonsCrand/orurineoutput.
These are functional parameters and may not be appropriate
for detection of injury to the kidney. We cannot rule out that
increased CyC levels indeed reﬂect damage to the kidneys
whichisnotrecognizedbytheRIFLEcriteria.Notably,inthe
present study, prevalence of AKI was high, and therefore a
low sCyC of\0.80 mg/L resulted in high [negative predic-
tive value (NPV) 75–95%] despite its low speciﬁcity.
Therefore, in a critically ill population with high prevalence
of AKI, sCyC may be helpful to rule out AKI.
Our study is the ﬁrst multicenter study investigating
whetherCyCcanpredictdevelopmentofAKIinthegeneral
criticalcaresettinginwhichthepopulationisheterogeneous
and AKI etiology and timing are often unclear. However,
there are some limitations. First, a small percentage of our
patients (12%) were enrolled the day following admission,
andspecimenswerecollectedonalternatedaysaftertheﬁrst
2 days. As a result, our sample size was relatively small,
particularly on Day –2. Second, MDRD-based baseline sCr
was used in 18% of our patients. Missing preadmission sCr
value is a recognized problem in AKI research, which may
lead to misclassiﬁcation of AKI incidence [41, 42]. On the
other hand, use of surrogate measures for baseline renal
function avoids selection bias. Third, we did not evaluate
whether CyC concentrations were affected by other factors
(e.g.,inﬂammatorystate,insulinorhydrocortisonetherapy).
Finally, the deﬁnition of AKI is critical in biomarker
research,andtheRIFLEcriteriamaynotbeanadequategold
standard for AKI.
Conclusions
In this relatively small multicenter study in a heteroge-
neous ICU population and using the RIFLE classiﬁcation
system to deﬁne AKI, sCyC and uCyC were poor bio-
markers for AKI. Moreover, on the ﬁrst day of AKI these
biomarkers did not predict the need of RRT. However,
sCyC\0.80 mg/L had high NPV in our population with
high incidence of AKI.
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